FR13C0012I1 - - Google Patents

Info

Publication number
FR13C0012I1
FR13C0012I1 FR13C0012C FR13C0012I1 FR 13C0012 I1 FR13C0012 I1 FR 13C0012I1 FR 13C0012 C FR13C0012 C FR 13C0012C FR 13C0012 I1 FR13C0012 I1 FR 13C0012I1
Authority
FR
France
Prior art keywords
ciprofloxacin
treatment
disclosed
aqueous suspension
formulations containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23261416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0012(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR13C0012I1 publication Critical patent/FR13C0012I1/fr
Application granted granted Critical
Publication of FR13C0012I2 publication Critical patent/FR13C0012I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane.
FR13C0012C 2001-09-21 2013-02-21 METHOD FOR TREATING MIDDLE EAR INFECTION Active FR13C0012I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32395101P 2001-09-21 2001-09-21
PCT/US2002/029373 WO2003026671A1 (en) 2001-09-21 2002-09-13 Method of treating middle ear infections

Publications (2)

Publication Number Publication Date
FR13C0012I1 true FR13C0012I1 (en) 2013-04-05
FR13C0012I2 FR13C0012I2 (en) 2014-02-14

Family

ID=23261416

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0012C Active FR13C0012I2 (en) 2001-09-21 2013-02-21 METHOD FOR TREATING MIDDLE EAR INFECTION

Country Status (19)

Country Link
US (8) US20030139382A1 (en)
EP (1) EP1429780B1 (en)
JP (1) JP2005504804A (en)
KR (1) KR20040035760A (en)
CN (1) CN1231218C (en)
AT (1) ATE313328T1 (en)
AU (1) AU2002333671B2 (en)
BR (1) BR0212898A (en)
CA (1) CA2459930C (en)
CY (1) CY1104988T1 (en)
DE (1) DE60208216T2 (en)
DK (1) DK1429780T3 (en)
ES (1) ES2250739T3 (en)
FR (1) FR13C0012I2 (en)
MX (1) MXPA04002576A (en)
PL (1) PL212457B1 (en)
RU (1) RU2295346C2 (en)
WO (1) WO2003026671A1 (en)
ZA (1) ZA200401847B (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2250739T3 (en) * 2001-09-21 2006-04-16 Alcon, Inc. METHOD FOR TREATING MID EAR INFECTIONS.
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
EP1776109B1 (en) 2004-08-13 2008-12-31 Schering-Plough Ltd. Pharmaceutical formulation comprising an antibiotic, a triazole and a corticosteroid
DE102005055385A1 (en) * 2004-12-09 2006-06-14 Bayer Healthcare Ag Medicines for hygienic application in the ear
US20070110788A1 (en) * 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
US20070264296A1 (en) * 2006-05-10 2007-11-15 Myntti Matthew F Biofilm extracellular polysachharide solvating system
US7976873B2 (en) 2006-05-10 2011-07-12 Medtronic Xomed, Inc. Extracellular polysaccharide solvating system for treatment of bacterial ear conditions
US7959943B2 (en) * 2006-05-10 2011-06-14 Medtronics Xomed, Inc. Solvating system and sealant for medical use in the middle or inner ear
US7993675B2 (en) * 2006-05-10 2011-08-09 Medtronic Xomed, Inc. Solvating system and sealant for medical use in the sinuses and nasal passages
US20080139545A1 (en) * 2006-05-22 2008-06-12 Won-Taek Choe Formulation to treat ear infection
WO2008085913A1 (en) * 2007-01-04 2008-07-17 Rib-X Pharmaceuticals, Inc. Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections
US8088095B2 (en) * 2007-02-08 2012-01-03 Medtronic Xomed, Inc. Polymeric sealant for medical use
US20090263345A1 (en) * 2008-01-28 2009-10-22 Foresight Biotherapeutics, Inc. Otic compositions for the treatment of infections of the internal and external ear in mammals
CA2723458C (en) 2008-05-14 2014-01-28 Otonomy, Inc. Controlled release corticosteroid compositions and methods for the treatment of otic disorders
AU2009257390B2 (en) 2008-06-12 2014-09-04 Medtronic Xomed, Inc. Method for treating chronic wounds with an extracellular polymeric substance solvating system
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
KR101367479B1 (en) * 2008-07-21 2014-03-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Controlled release antimicrobial compositions and methods for the treatment of otic disorders
WO2010042427A2 (en) 2008-10-06 2010-04-15 Microbial Defense Systems, Llc Antimicrobial composition and methods of making and using same
TW201023912A (en) * 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
CN105362221A (en) * 2009-03-03 2016-03-02 爱尔康研究有限公司 Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
US8912236B2 (en) * 2009-03-03 2014-12-16 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
CA2764809A1 (en) * 2009-06-08 2010-12-16 Otic Pharma Ltd. Otic foam formulations
WO2011049958A2 (en) * 2009-10-21 2011-04-28 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
JP6463629B2 (en) 2011-05-10 2019-02-06 ネクスト サイエンス アイピー ホールディングス ピーティワイ エルティーディ Antibacterial solid and method for producing the same
EP2938327B1 (en) * 2012-12-26 2017-12-06 Otic Pharma Ltd. Foamable otic pharmaceutical compositions
WO2015031393A1 (en) 2013-08-27 2015-03-05 Otonomy, Inc. Treatment of pediatric otic disorders
US20150119371A1 (en) * 2013-10-30 2015-04-30 Micro Labs Limited Topical pharmaceutical compositions of antibiotics and steroidal anti inflammatory agents
AU2015284048A1 (en) 2014-07-03 2017-02-16 Otonomy, Inc. Sterilization of ciprofloxacin composition
US9393243B1 (en) * 2015-07-14 2016-07-19 Nilesh Parikh Topical Ciprofloxacin compositions
EP3512513A4 (en) 2016-09-16 2020-04-15 Otonomy, Inc. Otic gel formulations for treating otitis externa
IT201900005280A1 (en) * 2019-04-05 2020-10-05 Ntc S R L Otological composition

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3134718A (en) * 1963-12-12 1964-05-26 Schering Corp Pregna-1,4-dienes and compositions containing same
US4670444B1 (en) * 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US5223493A (en) * 1984-12-28 1993-06-29 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
US4686214A (en) * 1985-10-30 1987-08-11 Alcon Laboratories, Inc. Anti-inflammatory compounds for ophthalmic use
DE3704907A1 (en) * 1987-02-17 1988-08-25 Bayer Ag TOPICALLY APPLICABLE PREPARATIONS OF GYRASE INHIBITORS IN COMBINATION WITH CORTICOSTEROIDS
WO1990001933A1 (en) * 1988-08-26 1990-03-08 Alcon Laboratories, Inc. Combination of quinolone antibiotics and steroids for topical ophthalmic use
ES2111083T3 (en) * 1991-09-17 1998-03-01 Alcon Lab Inc COMPOSITIONS CONTAINING QUINOLONE AND POLY (STIRENE SULPHONATE) ANTIBIOTICS.
ES2065846B1 (en) 1993-04-20 1995-10-01 Cusi Lab PHARMACEUTICAL FORMULATION BASED ON A STEROID OR NON-STEROID ANTI-INFLAMMATORY AGENT AND AN ANTIBIOTIC BELONGING TO THE GIRASE DNA INHIBITORS GROUP FOR ITS TOPICAL OPHTHALMIC USE.
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5420120A (en) * 1993-12-17 1995-05-30 Alcon Laboratories, Inc. Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
ES2078175B1 (en) 1993-12-31 1996-10-16 Cusi Lab PHARMACEUTICAL FORMULATION CONTAINING CLOBETASONE AND TOBRAMYCIN AND ITS APPLICATIONS.
ES2079320B1 (en) * 1994-05-17 1996-10-16 Cusi Lab OPHTHALMIC DISSOLUTION BASED ON A DICLOFENACO AND TOBRAMYCIN AND ITS APPLICATIONS.
US5843930A (en) * 1995-06-06 1998-12-01 Bayer Corporation Method of treating otitis with ciprofloxacin-hydrocortisone suspension
NZ309624A (en) 1995-06-06 1999-04-29 Bayer Ag Non-irritating, non-sensitizing, non-ototoxic (harmful to the ears) antibacterial compositions
DE19524691A1 (en) * 1995-07-06 1997-01-09 Liedtke Pharmed Gmbh Method and composition of topical therapy for inner ear and labyrinth symptoms
KR100508227B1 (en) 1997-03-14 2006-03-23 센주 세이야꾸 가부시키가이샤 Aqueous suspension of loteprednol etabonate
EP1117406A1 (en) 1998-09-30 2001-07-25 Alcon Laboratories, Inc. Antibiotic compositions for treatment of the eye, ear and nose
AR020661A1 (en) 1998-09-30 2002-05-22 Alcon Lab Inc A PHARMACEUTICAL COMPOSITION TOPICA OFTALMICA, OTICA OR NASAL AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
AR020660A1 (en) 1998-09-30 2002-05-22 Alcon Lab Inc ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF EYES, EARS AND NOSE
CN1158994C (en) * 1999-09-24 2004-07-28 爱尔康公司 Topcial suspension formulations containing ciprofloxacin and dexa methasone
ES2250739T3 (en) * 2001-09-21 2006-04-16 Alcon, Inc. METHOD FOR TREATING MID EAR INFECTIONS.

Also Published As

Publication number Publication date
US9402805B1 (en) 2016-08-02
ZA200401847B (en) 2005-05-25
BR0212898A (en) 2004-10-13
CY1104988T1 (en) 2009-11-04
CN1555267A (en) 2004-12-15
ES2250739T3 (en) 2006-04-16
US20140363511A1 (en) 2014-12-11
FR13C0012I2 (en) 2014-02-14
RU2295346C2 (en) 2007-03-20
CA2459930A1 (en) 2003-04-03
US20150374716A1 (en) 2015-12-31
US9345714B2 (en) 2016-05-24
US20160361324A1 (en) 2016-12-15
US20030139382A1 (en) 2003-07-24
RU2004111984A (en) 2005-02-27
JP2005504804A (en) 2005-02-17
EP1429780A1 (en) 2004-06-23
DE60208216D1 (en) 2006-01-26
US20080214513A1 (en) 2008-09-04
CA2459930C (en) 2009-11-10
CN1231218C (en) 2005-12-14
MXPA04002576A (en) 2004-06-18
PL369205A1 (en) 2005-04-18
DK1429780T3 (en) 2006-02-13
US20160243029A1 (en) 2016-08-25
ATE313328T1 (en) 2006-01-15
US20090156566A1 (en) 2009-06-18
US9149486B2 (en) 2015-10-06
US8846650B2 (en) 2014-09-30
WO2003026671A1 (en) 2003-04-03
EP1429780B1 (en) 2005-12-21
KR20040035760A (en) 2004-04-29
AU2002333671B2 (en) 2006-07-20
PL212457B1 (en) 2012-10-31
US20050059674A1 (en) 2005-03-17
DE60208216T2 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
FR13C0012I1 (en)
WO2004069156A3 (en) Inactivated probiotic bacteria and methods of use thereof
ATE340171T1 (en) PIPERAZINE DERIVATIVES FOR THE TREATMENT OF BACTERIAL INFECTIONS
AU2386201A (en) Substituted sapogenins and their use
DE60223254D1 (en) DELAYED FORCULATING FORMULATIONS OF OXYMORPHONE
AU2002305400A1 (en) Medical device and methods of use for glaucoma treatment
IL163573A0 (en) Conjugates of therapeutic or cytotoxic agents and biologically active peptides
MY128362A (en) Spontaneously dispersible n-benzoyl staurosporine compositions
IL145795A0 (en) Mutant human cd80 and compositions for and methods of making and using the same
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
AU2001259085A1 (en) Treatment of ocular neovascularization and related diseases
AU2002219881A1 (en) Methods and compositions for the treatment of human immunodeficiency virus infection
IL161501A0 (en) Methods of preventing and treating flavivirus infection in animals
GB9923078D0 (en) Sapogenin derivatives and their use
AUPQ344799A0 (en) Treatment of respiratory diseases and infections
AU5842300A (en) Pharmaceutical composition useful for the treatment of tinnitus and hearing loss
CZ20012085A3 (en) Use of riluzole when treating hearing disorders
WO2000027376A3 (en) Use of thiol compounds, oxidoreductases and/or hydrolases for the treatment of tinnitus, especially chronic tinnitus
AU7626800A (en) Middle-ear implant
UA36410A (en) Method for audiometry of human auditory system
EP3915593A3 (en) Ultraviolet light sanitizer
AU2001255056A1 (en) Vaccine for the treatment of tubercolosis and other intracellular infections diseases
AU1007401A (en) Treatment of respiratory diseases and infections
AUPR171000A0 (en) Composition for the treatment of infectious and/or skin diseases
AU2001265906A1 (en) Chemical alteration of mammal urine and mammal blood